Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018

Details for Mechanism ID: 18269
Country/Region: Haiti
Year: 2018
Main Partner: GHESKIO
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,600,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $638,486
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $638,486
Care: Pediatric Care and Support (PDCS) $127,697
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,064,142
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $343,429
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,574,931
Treatment: Pediatric Treatment (PDTX) $212,829
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 6
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 51
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 51
GEND_GBV Number of people receiving post-GBV care 2019 51
HTS_SELF 2019 1,232
HTS_SELF 15-19, Female, Directly-Assisted 2019 44
HTS_SELF 15-19, Female, Unassisted 2019 44
HTS_SELF 15-19, Male, Directly-Assisted 2019 44
HTS_SELF 15-19, Male, Unassisted 2019 44
HTS_SELF 20-24, Female, Directly-Assisted 2019 44
HTS_SELF 20-24, Female, Unassisted 2019 44
HTS_SELF 20-24, Male, Directly-Assisted 2019 44
HTS_SELF 20-24, Male, Unassisted 2019 44
HTS_SELF 25-29, Female, Directly-Assisted 2019 44
HTS_SELF 25-29, Female, Unassisted 2019 44
HTS_SELF 25-29, Male, Directly-Assisted 2019 44
HTS_SELF 25-29, Male, Unassisted 2019 44
HTS_SELF 30-34, Female, Directly-Assisted 2019 44
HTS_SELF 30-34, Female, Unassisted 2019 44
HTS_SELF 30-34, Male, Directly-Assisted 2019 44
HTS_SELF 30-34, Male, Unassisted 2019 44
HTS_SELF 35-39, Female, Directly-Assisted 2019 44
HTS_SELF 35-39, Female, Unassisted 2019 44
HTS_SELF 35-39, Male, Directly-Assisted 2019 44
HTS_SELF 35-39, Male, Unassisted 2019 44
HTS_SELF 40-49, Female, Directly-Assisted 2019 44
HTS_SELF 40-49, Female, Unassisted 2019 44
HTS_SELF 40-49, Male, Directly-Assisted 2019 44
HTS_SELF 40-49, Male, Unassisted 2019 44
HTS_SELF 50+, Female, Directly-Assisted 2019 44
HTS_SELF 50+, Female, Unassisted 2019 44
HTS_SELF 50+, Male, Directly-Assisted 2019 44
HTS_SELF 50+, Male, Unassisted 2019 44
HTS_SELF Directly-Assisted 2019 616
HTS_SELF Unassisted 2019 616
HTS_SELF Unassisted - Other 2019 199
HTS_SELF Unassisted - Self 2019 199
HTS_SELF Unassisted - Sex Partner 2019 218
HTS_TST <5, Unknown Sex, Negative 2019 667
HTS_TST 25-29, Female, Negative 2019 449
HTS_TST 25-29, Female, Negative 2019 271
HTS_TST 25-29, Female, Negative 2019 466
HTS_TST 25-29, Female, Negative 2019 3,156
HTS_TST 25-29, Female, Negative 2019 206
HTS_TST 25-29, Female, Negative 2019 4,032
HTS_TST 25-29, Male, Negative 2019 243
HTS_TST 25-29, Male, Negative 2019 146
HTS_TST 25-29, Male, Negative 2019 250
HTS_TST 25-29, Male, Negative 2019 113
HTS_TST 25-29, Male, Negative 2019 2,192
HTS_TST 30-34, Female, Negative 2019 449
HTS_TST 30-34, Female, Negative 2019 271
HTS_TST 30-34, Female, Negative 2019 466
HTS_TST 30-34, Female, Negative 2019 3,156
HTS_TST 30-34, Female, Negative 2019 206
HTS_TST 30-34, Female, Negative 2019 4,032
HTS_TST 30-34, Male, Negative 2019 243
HTS_TST 30-34, Male, Negative 2019 146
HTS_TST 30-34, Male, Negative 2019 250
HTS_TST 30-34, Male, Negative 2019 113
HTS_TST 30-34, Male, Negative 2019 2,192
HTS_TST 35-39, Female, Negative 2019 449
HTS_TST 35-39, Female, Negative 2019 271
HTS_TST 35-39, Female, Negative 2019 466
HTS_TST 35-39, Female, Negative 2019 3,156
HTS_TST 35-39, Female, Negative 2019 206
HTS_TST 35-39, Female, Negative 2019 4,032
HTS_TST 35-39, Male, Negative 2019 243
HTS_TST 35-39, Male, Negative 2019 146
HTS_TST 35-39, Male, Negative 2019 250
HTS_TST 35-39, Male, Negative 2019 113
HTS_TST 35-39, Male, Negative 2019 2,192
HTS_TST 40-49, Female, Negative 2019 447
HTS_TST 40-49, Female, Negative 2019 265
HTS_TST 40-49, Female, Negative 2019 466
HTS_TST 40-49, Female, Negative 2019 3,156
HTS_TST 40-49, Female, Negative 2019 204
HTS_TST 40-49, Female, Negative 2019 4,037
HTS_TST 40-49, Male, Negative 2019 244
HTS_TST 40-49, Male, Negative 2019 145
HTS_TST 40-49, Male, Negative 2019 255
HTS_TST 40-49, Male, Negative 2019 116
HTS_TST 40-49, Male, Negative 2019 2,191
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 76,859
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 690
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 1,557
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 2,415
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 172
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 1,658
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 709
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 911
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 68
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 46
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 274
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 159
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 311
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 221
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 63
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 616
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 118
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 338
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 43
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 27
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 158
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 91
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 176
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 123
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 68
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 47
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 284
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 165
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 334
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 236
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 5,381
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 93
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 32
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 21
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 126
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 74
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 145
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 106
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 627
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 410
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 2,471
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 1,429
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 2,743
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 1,955
HTS_TST_POS <5, Unknown Sex, Positive 2019 14
HTS_TST_POS 25-29, Female, Positive 2019 80
HTS_TST_POS 25-29, Female, Positive 2019 5
HTS_TST_POS 25-29, Female, Positive 2019 16
HTS_TST_POS 25-29, Female, Positive 2019 28
HTS_TST_POS 25-29, Female, Positive 2019 25
HTS_TST_POS 25-29, Female, Positive 2019 116
HTS_TST_POS 25-29, Male, Positive 2019 44
HTS_TST_POS 25-29, Male, Positive 2019 3
HTS_TST_POS 25-29, Male, Positive 2019 5
HTS_TST_POS 25-29, Male, Positive 2019 13
HTS_TST_POS 25-29, Male, Positive 2019 62
HTS_TST_POS 30-34, Female, Positive 2019 80
HTS_TST_POS 30-34, Female, Positive 2019 5
HTS_TST_POS 30-34, Female, Positive 2019 16
HTS_TST_POS 30-34, Female, Positive 2019 30
HTS_TST_POS 30-34, Female, Positive 2019 25
HTS_TST_POS 30-34, Female, Positive 2019 116
HTS_TST_POS 30-34, Male, Positive 2019 44
HTS_TST_POS 30-34, Male, Positive 2019 3
HTS_TST_POS 30-34, Male, Positive 2019 5
HTS_TST_POS 30-34, Male, Positive 2019 13
HTS_TST_POS 30-34, Male, Positive 2019 62
HTS_TST_POS 35-39, Female, Positive 2019 80
HTS_TST_POS 35-39, Female, Positive 2019 5
HTS_TST_POS 35-39, Female, Positive 2019 16
HTS_TST_POS 35-39, Female, Positive 2019 31
HTS_TST_POS 35-39, Female, Positive 2019 25
HTS_TST_POS 35-39, Female, Positive 2019 116
HTS_TST_POS 35-39, Male, Positive 2019 44
HTS_TST_POS 35-39, Male, Positive 2019 3
HTS_TST_POS 35-39, Male, Positive 2019 5
HTS_TST_POS 35-39, Male, Positive 2019 13
HTS_TST_POS 35-39, Male, Positive 2019 62
HTS_TST_POS 40-49, Female, Positive 2019 77
HTS_TST_POS 40-49, Female, Positive 2019 11
HTS_TST_POS 40-49, Female, Positive 2019 10
HTS_TST_POS 40-49, Female, Positive 2019 32
HTS_TST_POS 40-49, Female, Positive 2019 30
HTS_TST_POS 40-49, Female, Positive 2019 113
HTS_TST_POS 40-49, Male, Positive 2019 39
HTS_TST_POS 40-49, Male, Positive 2019 7
HTS_TST_POS 40-49, Male, Positive 2019 14
HTS_TST_POS 40-49, Male, Positive 2019 20
HTS_TST_POS 40-49, Male, Positive 2019 66
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 48
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 28
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 55
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 54
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 70
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 80
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 55
PMTCT_ART Already on ART at beginning of current pregnancy 2019 226
PMTCT_ART New on ART 2019 133
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 359
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 17,671
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 287
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 71
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 358
PMTCT_EID Sum of Infant Age disaggregates 2019 358
PMTCT_STAT 25-29, Female 2019 3,230
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 40
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 3,156
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 28
PMTCT_STAT 30-34, Female 2019 3,225
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 39
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 3,156
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 30
PMTCT_STAT 35-39, Female 2019 3,223
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 41
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 3,156
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 31
PMTCT_STAT 40-49, Female 2019 3,222
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 40
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 3,156
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 32
PMTCT_STAT By Age (Numerator): 15-19 2019 707
PMTCT_STAT By Age (Numerator): 20-24 2019 1,591
PMTCT_STAT By Age (Numerator): 50+ 2019 2,473
PMTCT_STAT By Number of known positives: 15-19 2019 8
PMTCT_STAT By Number of known positives: 20-24 2019 19
PMTCT_STAT By Number of known positives: 50+ 2019 30
PMTCT_STAT By Number of new negative: 15-19 2019 690
PMTCT_STAT By Number of new negative: 20-24 2019 1,557
PMTCT_STAT By Number of new negative: 50+ 2019 2,415
PMTCT_STAT By Number of new positives: 15-19 2019 5
PMTCT_STAT By Number of new positives: 20-24 2019 13
PMTCT_STAT By Number of new positives: 50+ 2019 22
PMTCT_STAT Number of new ANC and L&D clients 2019 17,671
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 17,671
PMTCT_STAT_den 25-29, Female 2019 3,230
PMTCT_STAT_den 30-34, Female 2019 3,225
PMTCT_STAT_den 35-39, Female 2019 3,223
PMTCT_STAT_den 40-49, Female 2019 3,222
PMTCT_STAT_den By Age (Denominator): <15-19 2019 707
PMTCT_STAT_den By Age (Denominator): 20-24 2019 1,591
PMTCT_STAT_den By Age (Denominator): 50+ 2019 2,473
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 15
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 305
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 9
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 180
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 509
TB_PREV By Age/Sex (Numerator): <15, Female 2019 65
TB_PREV By Age/Sex (Numerator): <15, Male 2019 45
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 1,311
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 765
TB_PREV IPT, Life-long ART, New, Positive 2019 2,186
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 2,186
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 2,428
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 73
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 48
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 1,458
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 849
TB_PREV_den IPT, Life-long ART, New, Positive 2019 2,428
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 70
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,398
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 46
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 815
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 2,329
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 2,329
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 70
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,398
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 46
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 815
TX_CURR 25-29, Female, Positive 2019 2,032
TX_CURR 25-29, Male, Positive 2019 1,132
TX_CURR 30-34, Female, Positive 2019 2,032
TX_CURR 30-34, Male, Positive 2019 1,132
TX_CURR 35-39, Female, Positive 2019 2,032
TX_CURR 35-39, Male, Positive 2019 1,132
TX_CURR 40-49, Female, Positive 2019 2,032
TX_CURR 40-49, Male, Positive 2019 1,132
TX_CURR Age/Sex: <1 2019 45
TX_CURR Age/Sex: <1-9 2019 446
TX_CURR Age/Sex: 10-14 Female 2019 234
TX_CURR Age/Sex: 10-14 Male 2019 182
TX_CURR Age/Sex: 15-19 Female 2019 312
TX_CURR Age/Sex: 15-19 Male 2019 211
TX_CURR Age/Sex: 20-24 Female 2019 1,231
TX_CURR Age/Sex: 20-24 Male 2019 718
TX_CURR Age/Sex: 50+ Female 2019 1,433
TX_CURR Age/Sex: 50+ Male 2019 1,093
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 18,561
TX_CURR Sum of age/sex disaggregates 2019 523
TX_NEW 25-29, Female, Positive 2019 283
TX_NEW 25-29, Male, Positive 2019 157
TX_NEW 30-34, Female, Positive 2019 283
TX_NEW 30-34, Male, Positive 2019 157
TX_NEW 35-39, Female, Positive 2019 283
TX_NEW 35-39, Male, Positive 2019 157
TX_NEW 40-49, Female, Positive 2019 283
TX_NEW 40-49, Male, Positive 2019 157
TX_NEW Breastfeeding status 2019 30
TX_NEW By Age/Sex: <1 2019 11
TX_NEW By Age/Sex: 1-9 2019 109
TX_NEW By Age/Sex: 10-14 Female 2019 59
TX_NEW By Age/Sex: 10-14 Male 2019 45
TX_NEW By Age/Sex: 15-19 Female 2019 45
TX_NEW By Age/Sex: 15-19 Male 2019 29
TX_NEW By Age/Sex: 20-24 Female 2019 172
TX_NEW By Age/Sex: 20-24 Male 2019 101
TX_NEW By Age/Sex: 50+ Female 2019 197
TX_NEW By Age/Sex: 50+ Male 2019 158
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 2,686
TX_NEW Pregnancy status 2019 134
TX_NEW Sum of Age/Sex disaggregates 2019 806
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 17,700
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 477
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 54
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 319
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 37
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 9,556
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 1,061
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 5,577
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 619
TX_PVLS_den Denominator: Indication: Routine 2019 15,929
TX_PVLS_den Denominator: Indication: Targeted 2019 1,771
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 81
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 54
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,622
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 947
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 2,704
TX_RET Numerator by Status: Breastfeeding 2019 32
TX_RET Numerator by Status: Pregnant 2019 270
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 2,704
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 81
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 54
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,622
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 947
TX_RET_den Denominator by Status: Breastfeeding 2019 32
TX_RET_den Denominator by Status: Pregnant 2019 270
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 18,953
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 570
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 381
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 11,371
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 6,631
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 303
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 25
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 428
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 756
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 14,723
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 615
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 3,467
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 145